SG11202110990RA - Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease - Google Patents

Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Info

Publication number
SG11202110990RA
SG11202110990RA SG11202110990RA SG11202110990RA SG11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA
Authority
SG
Singapore
Prior art keywords
antibodies
treating
methods
neurodegenerative disease
modified anti
Prior art date
Application number
SG11202110990RA
Other languages
English (en)
Inventor
Ester Yoles
Berit Olsen Krogh
Allan Jensen
Jan Egebjerg
Carol David
Kuti Baruch
Michal Eisenbach-Schwartz
Original Assignee
Immunobrain Checkpoint Inc
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobrain Checkpoint Inc, Yeda Res & Dev filed Critical Immunobrain Checkpoint Inc
Publication of SG11202110990RA publication Critical patent/SG11202110990RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202110990RA 2019-04-19 2020-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease SG11202110990RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836247P 2019-04-19 2019-04-19
EP19170438.6A EP3725370A1 (fr) 2019-04-19 2019-04-19 Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative
PCT/US2020/028900 WO2020215049A1 (fr) 2019-04-19 2020-04-19 Anticorps anti-pd-l1 modifiés et méthodes et utilisations pour le traitement d'une maladie neurodégénérative

Publications (1)

Publication Number Publication Date
SG11202110990RA true SG11202110990RA (en) 2021-10-28

Family

ID=66240002

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110990RA SG11202110990RA (en) 2019-04-19 2020-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Country Status (14)

Country Link
US (3) US10995141B2 (fr)
EP (2) EP3725370A1 (fr)
JP (1) JP2022529789A (fr)
KR (1) KR20220002972A (fr)
CN (1) CN114007645A (fr)
AU (1) AU2020257283A1 (fr)
BR (1) BR112021020947A2 (fr)
CA (1) CA3137143A1 (fr)
CL (1) CL2021002735A1 (fr)
IL (1) IL287008A (fr)
MX (1) MX2021012783A (fr)
SG (1) SG11202110990RA (fr)
WO (1) WO2020215049A1 (fr)
ZA (1) ZA202109173B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144778B2 (en) * 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN117136073A (zh) * 2021-02-14 2023-11-28 普罗塞纳生物科学有限公司 使用识别tau的抗体的方法

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP3287144A1 (fr) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Compositions immunostimulantes
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
AU2004288654B2 (en) 2003-11-12 2009-12-03 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP3363907A1 (fr) 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Nouvel antigène artificiel présentant des cellules et utilisations associées
CA2970873C (fr) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20100061992A1 (en) 2006-11-15 2010-03-11 The Brigham And Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
EP3222634A1 (fr) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
WO2009094273A2 (fr) 2008-01-15 2009-07-30 Yale University Compositions et procédés pour une immunothérapie adoptive et active
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027423A2 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
CA2736829C (fr) 2008-09-12 2018-02-27 Isis Innovation Limited Anticorps specifiques de pd-1 et leurs utilisations
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
MX2012005300A (es) 2009-11-06 2012-07-30 David Gladstone Inst Metodos y composiciones para modula niveles de tau.
CA2791930A1 (fr) 2010-03-11 2011-09-15 Kerry Louise Tyson Anticorps pd-1
US8835613B2 (en) 2010-03-12 2014-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
US20130323283A1 (en) 2010-12-01 2013-12-05 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
EP2688890B1 (fr) 2011-03-22 2017-08-30 Advinus Therapeutics Limited Composés tricycliques substitués; compositions et applications médicinales correspondantes
TR201810298T4 (tr) 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
EP2739649B1 (fr) 2011-08-05 2017-09-27 Bioasis Technologies Inc. Fragments de p97 avec activité de transfert
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
MX352823B (es) 2011-10-28 2017-12-04 Integritybio Inc Formulaciones de proteinas que contienen aminoacidos.
WO2013090552A1 (fr) 2011-12-13 2013-06-20 Yale University Compositions et procédés pour la réduction de l'épuisement de ctl
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013142255A2 (fr) 2012-03-22 2013-09-26 University Of Miami Agents de liaison multi-spécifiques
ES2607148T3 (es) 2012-05-08 2017-03-29 The Johns Hopkins University Métodos y composiciones para infusión de poblaciones seleccionadas de linfocitos alogénicos con prendimiento transitorio para tratar cáncer
WO2013190555A1 (fr) 2012-06-21 2013-12-27 Compugen Ltd. Anticorps anti-lsr et leurs utilisations pour le traitement du cancer
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2916638C (fr) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation de la reponse immunitaire
WO2014028502A1 (fr) 2012-08-13 2014-02-20 ImmunGene Inc. Molécules de fusion anticorps-interféron génétiquement modifiées pour le traitement de maladies auto-immunes
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150238582A1 (en) 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
JP6356134B2 (ja) 2012-10-12 2018-07-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の増強
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
WO2014074852A1 (fr) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions et procédés modulant une réponse immunitaire
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CA2895284A1 (fr) 2013-02-07 2014-08-14 Immunomedics, Inc. Forme de pro-medicament (p2pdox) de la 2-pyrrolinodoxorubicine fortement puissante conjuguee a des anticorps pour la therapie ciblee du cancer
BR112015018989B1 (pt) 2013-02-22 2023-11-14 Curevac Ag Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
HUE044238T2 (hu) 2013-03-13 2019-10-28 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
EP2970908B1 (fr) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
EP2970436B1 (fr) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Variants de fc
EP3607974A1 (fr) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Vaccins contre le cancer et procédés de traitement les utilisant
WO2014161509A1 (fr) 2013-04-05 2014-10-09 The University Of Hong Kong Nouveaux isoformes de la pd1 et leurs utilisations pour potentialiser les réponses immunitaires
EP2992017B1 (fr) 2013-05-02 2020-11-18 AnaptysBio, Inc. Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
EP4119662A1 (fr) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Modification de protéine de cellules vivantes utilisant la sortase
JP6563906B2 (ja) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−１に結合する抗原結合蛋白質
WO2014204762A1 (fr) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology Ciblage in vivo de cellules avec des particules conjuguées à un ligand
US9616129B2 (en) 2013-06-22 2017-04-11 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2014209804A1 (fr) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Anticorps bispécifiques
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
PL3021869T3 (pl) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
US11273204B2 (en) 2013-08-08 2022-03-15 Cytune Pharma IL-15 and IL-15RAPLHA sushi domain based immunocytokines
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015024060A1 (fr) 2013-08-22 2015-02-26 The Council Of The Queensland Institute Of Medical Research Modulation d'immunorécepteur destinée au traitement de cancer et d'infections virales
EP3036255A4 (fr) 2013-08-22 2017-03-22 The Council Of The Queensland Institute Of Medical Research Modulation d'immunorécepteur permettant le traitement de cancer et d'infections virales
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
MX2016005283A (es) 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20150165021A1 (en) 2013-11-05 2015-06-18 Nkt Therapeutics Inc. Combination therapy
WO2015084721A1 (fr) 2013-12-02 2015-06-11 Tabaczynski David A Inhibition de voies de biosynthèse d'isoprénoïdes pour traiter des troubles auto-immuns
EP3082802B1 (fr) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Inhibiteurs de la tryptophane-2,3-dioxygénase (tdo) et/ou de l'indolamine-2,3-dioxygénase et leur utilisation
ES2755129T3 (es) 2013-12-06 2020-04-21 Dana Farber Cancer Inst Inc Péptidos terapéuticos
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
PL3192812T3 (pl) 2013-12-17 2020-10-19 Genentech, Inc. Przeciwciała anty-CD3 i sposoby ich zastosowania
EP3083671B1 (fr) 2013-12-20 2020-09-30 Fred Hutchinson Cancer Research Center Molécules effectrices chimériques marquées et leurs récepteurs
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015103602A1 (fr) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunothérapie
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2017042633A2 (fr) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Réduction des quantités ou de l'activité de cellules t régulatrices systémiques pour le traitement de maladie et de lésion du snc
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
SG11201610074YA (en) 2014-06-06 2016-12-29 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017218435A1 (fr) * 2016-06-13 2017-12-21 Askgene Pharma Inc. Anticorps monoclonaux spécifiques de pd-l1 pour le traitement et le diagnostic de maladies
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
SG11201811064TA (en) * 2016-06-20 2019-01-30 F Star Delta Ltd Binding molecules binding pd-l1 and lag-3
EP3360898A1 (fr) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
CA3064321A1 (fr) * 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Anticorps comprenant des regions constantes de chaine lourde modifiees
JP2020523319A (ja) 2017-06-07 2020-08-06 シルバーバック セラピューティックス インコーポレイテッド 免疫調節化合物の抗体コンジュゲートおよびその使用
WO2019096136A1 (fr) * 2017-11-14 2019-05-23 拜西欧斯（北京）生物技术有限公司 Anticorps anti-pd-1, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
US11732046B2 (en) 2023-08-22
KR20220002972A (ko) 2022-01-07
BR112021020947A2 (pt) 2022-04-05
CA3137143A1 (fr) 2020-10-22
US20210221893A1 (en) 2021-07-22
JP2022529789A (ja) 2022-06-24
AU2020257283A1 (en) 2021-12-16
ZA202109173B (en) 2023-04-26
EP3955961A4 (fr) 2023-06-14
CL2021002735A1 (es) 2022-05-20
US20240052038A1 (en) 2024-02-15
IL287008A (en) 2021-12-01
EP3725370A1 (fr) 2020-10-21
WO2020215049A1 (fr) 2020-10-22
EP3955961A1 (fr) 2022-02-23
CN114007645A (zh) 2022-02-01
MX2021012783A (es) 2022-02-10
US10995141B2 (en) 2021-05-04
US20200332011A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL279974A (en) Anti-BCMA and anti-CD3 bispecific antibodies and their uses
IL283530A (en) Bispecific anti-pd-l1/anti-4-1bb antibodies and their uses
IL276872A (en) Dosage for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL281449A (en) Anti-ifnar1 antibodies for the treatment of autoimmune diseases
ZA202109173B (en) Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
IL280757A (en) Monoclonal antibodies against human TIM-3
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
IL286690A (en) Antibodies against egfrviii and antigen-binding fragments thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
EP4083069A4 (fr) Anticorps anti-ox40 et utilisation associée
IL291661A (en) Dosage for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
IL266106A (en) Monoclonal antibody and method of use for treatment of lupus
IL277296A (en) Antibodies against PFRH5 and their antigen-binding fragments
EP3930711A4 (fr) Matériaux et procédés de traitement d'une maladie neurodégénérative
EP4034568A4 (fr) Nouveaux anticorps contre pd-l1
GB201910138D0 (en) Anti-pd-l1 antibodies
GB201911211D0 (en) Monoclonal antibodies against ambra-1
IL308393A (en) Antibodies for the treatment of alpha-synuclein diseases
ZA202210284B (en) Anti-trem1 antibodies and related methods
GB201906538D0 (en) Anti-pd-1 antibodies
EP3904383A4 (fr) Anticorps monoclonal anti-ox40 et utilisation associée